Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who were living in Réunion at the time their breast cancer was diagnosed
- People diagnosed with a first breast cancer (either contained in one area or spreading) confirmed by laboratory testing of tissue samples, during the study enrollment period
- People diagnosed with a second breast cancer (either contained in one area or spreading) confirmed by laboratory testing of tissue samples, where the second cancer is in the opposite breast, or occurred at least 5 years after the first cancer was in remission
- People who have agreed to take part in the study
- People who are members of, or covered by, a French social security scheme
Who may not be able to join:
- People whose breast condition is a lymphoma (a type of cancer affecting the lymph system) rather than a typical breast cancer
- People who are under 18 years old, or who are under legal guardianship or court-appointed protection
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 0262906283
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
determine the prevalence of the Réunion mutation in the BRCA2 gene (c.2612C>A mutation of exon 11) in the population of individuals residing in Réunion who are diagnosed with breast cancer.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.